Acuta Capital Partners’s BioCryst Pharmaceuticals BCRX Stock Holding History

Acuta Capital Partners’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-660,000	Closed	-$2.27M	–	52
2020 Q3	$2.27M	Sell	660,000 -1,240,000	-65%	-$5.31M	0.62%	38
2020 Q2	$9.05M	Buy	1,900,000 +1,650,000	+660%	+$6.59M	2.62%	12
2020 Q1	$500K	Sell	250,000 -2,575,000	-91%	-$7.09M	0.24%	30
2019 Q4	$9.75M	Buy	+2,825,000	New	+$7.11M	2.41%	13
2019 Q2	–	Sell	-25,000	Closed	-$204K	–	34
2019 Q1	$204K	Hold	25,000	–	–	0.1%	32
2018 Q4	$202K	Buy	+25,000	New	+$194K	0.15%	20
2018 Q1	–	Sell	-900,000	Closed	-$4.42M	–	65
2017 Q4	$4.42M	Sell	900,000 -96,300	-10%	-$467K	0.83%	20
2017 Q3	$5.22M	Buy	996,300 +827,615	+491%	+$4.24M	0.94%	23
2017 Q2	$938K	Sell	168,685 -751,625	-82%	-$4.58M	0.26%	44
2017 Q1	$7.73M	Buy	920,310 +770,310	+514%	+$5.36M	1.83%	13
2016 Q4	$950K	Sell	150,000 -404,448	-73%	-$2.1M	0.35%	36
2016 Q3	$2.44M	Buy	+554,448	New	+$2.21M	0.92%	30
2015 Q4	–	Sell	-271,399	Closed	-$3.09M	–	59
2015 Q3	$3.09M	Buy	+271,399	New	+$3.62M	1.79%	19

Other funds holding BCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

OIM

Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

MWNA

Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return

Acuta Capital Partners's BCRX Position: Q4 2020 in Review

Acuta Capital Partners sold out of BioCryst Pharmaceuticals (BCRX) in Q4 2020, closing a stake of 660,000 shares — an estimated $2.27M sold.

Acuta Capital Partners first reported a position in BCRX in Q3 2015 and held it in 13 quarters. The position peaked at $9.75M in Q4 2019. 177 funds tracked by Wall St. Rank hold BCRX as of Q4 2020.

Acuta Capital Partners reported no remaining BioCryst Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
Acuta Capital Partners sold 660,000 BioCryst Pharmaceuticals shares in Q4 2020, an estimated $2.27M.
Acuta Capital Partners first reported a position in BioCryst Pharmaceuticals in Q3 2015 and held it in 13 quarters.
Acuta Capital Partners's BioCryst Pharmaceuticals position peaked at $9.75M in Q4 2019.
177 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q4 2020.

Based on Acuta Capital Partners's 13F filing for Q4 2020, filed 16 Feb 2021.